We are live on
!
Find out more
OM
Opaleye Management Portfolio holdings
AUM
$1.1B
Turnover
32.84%
1-Year Est. Return
197.64%
This Fund
S&P 500
This Quarter
Est. Return
-24.99%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$160M
AUM Growth
-$78.8M
(-33%)
Cap. Flow
-$21.6M
Cap. Flow
% of AUM
-13.46%
Top 10 Holdings %
Top 10 Hldgs %
42.9%
Holding
67
New
14
Increased
18
Reduced
12
Closed
14
Avg Time Held
0.7
years
Top 10 Avg Time Held
0.5
years
Top 20 Avg Time Held
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Agios Pharmaceuticals
AGIO
|
+$4.49M |
| 2 |
Chimerix, Inc.
CMRX
|
+$4.41M |
| 3 |
Tvardi Therapeutics
TVRD
|
+$3.55M |
| 4 |
IMMU
Immunomedics Inc
IMMU
|
+$2.33M |
| 5 |
Sage Therapeutics
SAGE
|
+$2.29M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RLYP
RELYPSA INC COM
RLYP
|
+$6.24M |
| 2 |
CEMP
Cempra, Inc.
CEMP
|
+$6.23M |
| 3 |
Tonix Pharmaceuticals
TNXP
|
+$4.33M |
| 4 |
Avinger, Inc. Common Stock
AVGR
|
+$4.32M |
| 5 |
Supernus Pharmaceuticals
SUPN
|
+$3.85M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.12% |
| 2 | Miscellaneous | 11.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
DELISTED
Affimed
AFMD
| $2.28M | 1.42% |
61,000
+1,500
| +3% | +$56.5K |
2015 Q2
3 quarters
|
|
|
ZGNX
27
DELISTED
Zogenix, Inc.
ZGNX
| $2.22M | 1.38% |
240,000
+90,000
| +60% | +$902K |
2015 Q2
3 quarters
|
|
28
Travere Therapeutics
TVTX
$4.98B
| $2.05M | 1.28% |
150,000
-195,000
| -57% | -$2.96M |
2014 Q1
8 quarters
|
|
|
29
Supernus Pharmaceuticals
SUPN
$2.32B
| $1.91M | 1.19% |
125,000
-295,000
| -70% | -$3.85M |
2014 Q4
5 quarters
|
|
|
TRIL
30
DELISTED
Trillium Therapeutics Inc.
TRIL
| $1.8M | 1.13% |
195,000
-15,000
| -7% | -$126K |
2014 Q4
5 quarters
|
|
31
PDS Biotechnology
PDSB
$97.8M
| $1.69M | 1.06% |
+9,250
| New | +$1.65M |
2016 Q1
0 quarters
|
|
|
CYNA
32
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
| $1.44M | 0.9% |
121,000
+11,000
| +10% | +$147K |
2015 Q3
2 quarters
|
|
|
ADAP
33
DELISTED
Adaptimmune Therapeutics
ADAP
| $1.43M | 0.89% |
+175,300
| New | +$1.43M |
2016 Q1
0 quarters
|
|
|
CORI
34
DELISTED
Corium International, Inc.
CORI
| $1.39M | 0.87% |
360,000
+5,000
| +1% | +$26.3K |
2015 Q4
1 quarter
|
|
35
DELISTED
Altamira Therapeutics Ltd
CYTO
| $1.24M | 0.77% |
4
-1
| -20% | -$356K |
2015 Q2
3 quarters
|
|
36
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
| $1.18M | 0.73% |
+915
| New | +$1.3M |
2016 Q1
0 quarters
|
|
37
DELISTED
Xoma
XOMA
| $1.04M | 0.65% |
67,500
-17,500
| -21% | -$315K |
2015 Q2
3 quarters
|
|
38
Tenax Therapeutics
TENX
$57.3M
| $1.02M | 0.64% |
16
-1
| -6% | -$77.7K |
2014 Q4
5 quarters
|
|
|
AKAO
39
DELISTED
Achaogen Inc
AKAO
| $704K | 0.44% |
+255,000
| New | +$991K |
2016 Q1
0 quarters
|
|
40
Nektar Therapeutics
NKTR
$1.29B
| $688K | 0.43% |
+3,333
| New | +$640K |
2016 Q1
0 quarters
|
|
|
MDVN
41
DELISTED
MEDIVATION, INC.
MDVN
| $667K | 0.42% |
+14,500
| New | +$526K |
2016 Q1
0 quarters
|
|
42
DELISTED
Evoke Pharma
EVOK
| $662K | 0.41% |
903
| – | – |
2014 Q1
8 quarters
|
|
43
Prothena Corp
PRTA
$438M
| $576K | 0.36% |
+14,000
| New | +$548K |
2016 Q1
0 quarters
|
|
|
NDRM
44
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $544K | 0.34% |
+38,500
| New | +$520K |
2016 Q1
0 quarters
|
|
45
DELISTED
Alpine Immune Sciences Inc
ALPN
| $417K | 0.26% |
+25,000
| New | +$501K |
2016 Q1
0 quarters
|
|
46
Aclaris Therapeutics
ACRS
$509M
| $341K | 0.21% |
+18,000
| New | +$344K |
2016 Q1
0 quarters
|
|
47
BioLineRX
BLRX
$9.81M
| $255K | 0.16% |
417
| – | – |
2013 Q4
9 quarters
|
|
|
CHMA
48
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $183K | 0.11% |
+20,000
| New | +$216K |
2016 Q1
0 quarters
|
|
|
AVDL
49
DELISTED
Avadel Pharmaceuticals
AVDL
| – | – |
-250,000
| Closed | -$3.05M | – |
|
50
DELISTED
Accelerate Diagnostics
AXDX
| – | – |
-7,500
| Closed | -$1.61M | – |
|
Similar funds
CFO
PFM
HBCM
AI
TPA
ZDA
NW
TFA
Opaleye Management's Q1 2016 Portfolio in Review
As of Q1 2016, Opaleye Management held 67 positions worth $160M, down 33% from $239M the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Opaleye Management withdrew a net $21.6M in Q1 2016, closing 14 positions and reducing 12 holdings. Its most notable exit was RELYPSA INC COM, an estimated $6.24M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 88% a quarter earlier, followed by Miscellaneous.
Against the trend, Opaleye Management opened a new position in Agios Pharmaceuticals worth $4.26M.
- Opaleye Management's largest Q1 2016 buy was Agios Pharmaceuticals: 105,000 shares worth $4.26M.
- Opaleye Management added most to Tvardi Therapeutics in Q1 2016, an estimated $3.55M increase.
- Opaleye Management's biggest Q1 2016 reduction was Supernus Pharmaceuticals, cutting an estimated $3.85M.
- Opaleye Management fully exited RELYPSA INC COM in Q1 2016, selling an estimated $6.24M.
- Opaleye Management's ten largest holdings make up 43% of its $160M portfolio in Q1 2016.
- Opaleye Management opened 14 new positions and closed 14 in Q1 2016.
- Opaleye Management's portfolio value fell 33% quarter-over-quarter to $160M.
Based on Opaleye Management's 13F filing for Q1 2016, filed 16 May 2016.